Literature DB >> 16788383

Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

David F Barker1, Anwar Husain, Jason R Neale, Benjamin D Martini, Xiaoyan Zhang, Mark A Doll, J Christopher States, David W Hein.   

Abstract

Variable expression of human arylamine N-acetyltransferase 1 (NAT1) due to genetic polymorphism, gene regulation or environmental influences is associated with individual susceptibility to various cancers. Recent studies of NAT1 transcription showed that most mRNAs originate at a promoter, P1, located 11.8 kb upstream of the single open reading frame (ORF) exon. We have now characterized an alternative NAT1 promoter lying 51.5 kb upstream of the NAT1 ORF. In the present study, analysis of human RNAs representing 27 tissue types by reverse transcriptase-polymerase chain reaction (RT-PCR) and quantitative RT-PCR showed the upstream 51.5 kb promoter, designated P3, to be most active in specific tissues, including kidney, liver, lung, and trachea. All NAT1 P3 mRNAs included 5'-untranslated region (5'-UTR) internal exons of 61 and 175 nucleotides in addition to the 79 nucleotide 5'-UTR exon present in P1 mRNA. CAP-dependent amplification of 5'-P3 mRNA termini defined an 84 bp transcription start region in which most start sites are centrally clustered. The hepatoma-derived HepG2 cell line expressed a high level of P3 mRNA with the same spliced structure and start site pattern as found in normal tissues. A 435-bp minimal promoter was defined by transfection of HepG2 with luciferase expression constructs containing genomic fragments from the P3 start region. These findings imply a fundamental role for P3 in NAT1 regulation and define additional regions for genetic polymorphisms associated with enhanced cancer risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788383      PMCID: PMC1955765          DOI: 10.1097/01.fpc.0000215066.29342.26

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  43 in total

1.  Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1.

Authors:  J H de León; K P Vatsis; W W Weber
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

2.  Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.

Authors:  I Cascorbi; I Roots; J Brockmöller
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1).

Authors:  C Bruhn; J Brockmöller; I Cascorbi; I Roots; H H Borchert
Journal:  Biochem Pharmacol       Date:  1999-12-01       Impact factor: 5.858

4.  N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women.

Authors:  A C Deitz; W Zheng; M A Leff; M Gross; W Q Wen; M A Doll; G H Xiao; A R Folsom; D W Hein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-09       Impact factor: 4.254

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  NAT1*10 and NAT1*11 polymorphisms and breast cancer risk.

Authors:  R C Millikan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-02       Impact factor: 4.254

7.  Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells.

Authors:  N J Butcher; K F Ilett; R F Minchin
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

8.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

9.  Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay.

Authors:  J M Lo-Guidice; D Allorge; D Chevalier; H Debuysère; F Fazio; L J Lafitte; F Broly
Journal:  Pharmacogenetics       Date:  2000-06

10.  Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos.

Authors:  V A Smelt; A Upton; J Adjaye; M A Payton; S Boukouvala; N Johnson; H J Mardon; E Sim
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

View more
  22 in total

1.  NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

2.  Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter.

Authors:  Barbara Bonamassa; Yongjie Ma; Dexi Liu
Journal:  AAPS J       Date:  2012-05-30       Impact factor: 4.009

3.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

4.  Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function.

Authors:  Jason M Walraven; John O Trent; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-03-19       Impact factor: 3.922

5.  Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.

Authors:  Danxin Wang; Michael F Para; Susan L Koletar; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

6.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

7.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

8.  Inflammatory cytokines suppress arylamine N-acetyltransferase 1 in cholangiocarcinoma cells.

Authors:  Benjaporn Buranrat; Auemduan Prawan; Banchob Sripa; Veerapol Kukongviriyapan
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

9.  Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat.

Authors:  David W Hein; Jean Bendaly; Jason R Neale; Mark A Doll
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

10.  Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and Functional characterization of a novel rNat3*2 genetic variant.

Authors:  Jason M Walraven; David F Barker; Mark A Doll; David W Hein
Journal:  Toxicol Sci       Date:  2007-06-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.